The global. regional, and National burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:42–54.

Article  Google Scholar 

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.

Article  CAS  PubMed  Google Scholar 

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.

Article  CAS  PubMed  Google Scholar 

Kang YK, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1045–56.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

Article  PubMed  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.

Article  CAS  PubMed  Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–68.

Article  CAS  PubMed  Google Scholar 

Huch M, Koo BK. Modeling mouse and human development using organoid cultures. Development. 2015;142:3113–25.

Article  CAS  PubMed  Google Scholar 

Shamir ER, Ewald AJ. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol. 2014;15:647–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11:116.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Kong Y, Cui J, Hou Y, Gu Z, Ma C. Advances and applications of Cancer organoids in drug screening and personalized medicine. Stem Cell Rev Rep. 2024;20:1213–26.

Article  PubMed  Google Scholar 

Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids Nat Rev Methods Primers. 2022;2:94.

Article  CAS  PubMed  Google Scholar 

Pang MJ, Burclaff JR, Jin R, Adkins-Threats M, Osaki LH, Han Y, et al. Gastric organoids: progress and remaining challenges. Cell Mol Gastroenterol Hepatol. 2022;13:19–33.

Article  CAS  PubMed  Google Scholar 

Koh V, Chakrabarti J, Torvund M, Steele N, Hawkins JA, Ito Y, et al. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 2021;518:59–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, et al. A comprehensive human gastric Cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell. 2018;23:882–97.

Article  CAS  PubMed  Google Scholar 

Harada K, Sakamoto N, Ukai S, Yamamoto Y, Pham QT, Taniyama D, et al. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of Myoferlin in the acquisition of oxaliplatin resistance. Gastric Cancer. 2021;24:1264–77.

Article  CAS  PubMed  Google Scholar 

Andersson-Rolf A, Mustata RC, Merenda A, Kim J, Perera S, Grego T, et al. One-step generation of conditional and reversible gene knockouts. Nat Methods. 2017;14:287–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koo BK, Stange DE, Sato T, Karthaus W, Farin HF, Huch M, et al. Controlled gene expression in primary Lgr5 organoid cultures. Nat Methods. 2011;9:81–3.

Article  PubMed  Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.

Article  CAS  PubMed  Google Scholar 

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20.

Article  CAS  PubMed  Google Scholar 

Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44:127–72.

Article  CAS  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  CAS  PubMed  Google Scholar 

Xu Z, Hu C, Chen S, Zhang C, Yu J, Wang X, et al. Apatinib enhances chemosensitivity of gastric cancer to Paclitaxel and 5-fluorouracil. Cancer Manag Res. 2019;11:4905–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Wu X, Li F, Wang N, Zhang M, Sun T, et al. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer. J Cancer Res Ther. 2019;15:365–9.

Article  CAS  PubMed  Google Scholar 

Takada H, Sasagawa Y, Yoshimura M, Tanaka K, Iwayama Y, Hayashi T, et al. Single-cell transcriptomics uncovers EGFR signaling-mediated gastric progenitor cell differentiation in stomach homeostasis. Nat Commun. 2023;14:3750.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7:358.

Article  PubMed  PubMed Central  Google Scholar 

Qi C, Chong X, Zhou T, Ma M, Gong J, Zhang M, et al. Clinicopathological significance and immunotherapeutic outcome of Claudin 18.2 expression in advanced gastric cancer: A retrospective study. Chin J Cancer Res. 2024;36:78–89.

Article  PubMed  PubMed Central  Google Scholar 

Antibody Improves Survival in Gastric Cancer. Cancer Discov. 2016;6:Of8.

Google Scholar